Esketamine: Postmarketing Safety Concerns

Psychopharmacology and Psychiatry Updates - Ein Podcast von Psychopharmacology Institute

How risky is esketamine? In this episode, we examine the safety of esketamine using postmarketing data that have been reported since the drug was approved and released. Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 27 Postmarketing Safety Concerns With Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System  

Visit the podcast's native language site